Tuesday 12 May 2020
18:00
Professor Sir John Bell
Regius Professor of Medicine at Oxford University and Government Advisor on Life Sciences
Diana will be getting together with Professor Sir John Bell to discuss where we are with the UK response to Covid, including developments in the testing regime and prospects for other medical interventions.
John Bell is Regius Professor of Medicine at Oxford University and Government Advisor on Life Sciences. He is Chairman of the Gates Foundation Global Health Advisory Board and sits on the board of Genomics England Limited.
His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics.
John led the UK Life Sciences Industrial Strategy between 2015-2019, was President of the Academy of Medical Sciences and has helped to create (either as Founder or Founding Director) 5 Biotech companies. He was a Board Member at Roche AG for 19 years.
"We clearly want to avoid telling people they are immune when they are not, and we want all people who are immune to know accurately so they can get back to work."
John Bell is Regius Professor of Medicine at Oxford University and Government Advisor on Life Sciences. He is Chairman of the Gates Foundation Global Health Advisory Board and sits on the board of Genomics England Limited.
His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics.
John led the UK Life Sciences Industrial Strategy between 2015-2019, was President of the Academy of Medical Sciences and has helped to create (either as Founder or Founding Director) 5 Biotech companies. He was a Board Member at Roche AG for 19 years.
